Novavax Inc (NVAX)
4.365
+0.08
(+1.75%)
USD |
NASDAQ |
Apr 30, 15:24
Novavax Cash from Financing (Quarterly): 100.39M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 100.39M |
| September 30, 2023 | 197.12M |
| June 30, 2023 | 61.34M |
| March 31, 2023 | -354.38M |
| December 31, 2022 | 191.44M |
| September 30, 2022 | -30.98M |
| June 30, 2022 | 4.659M |
| March 31, 2022 | 159.86M |
| December 31, 2021 | -60.71M |
| September 30, 2021 | -15.72M |
| June 30, 2021 | -38.84M |
| March 31, 2021 | 576.99M |
| December 31, 2020 | 404.61M |
| September 30, 2020 | -22.39M |
| June 30, 2020 | 416.62M |
| March 31, 2020 | 185.92M |
| December 31, 2019 | 30.17M |
| September 30, 2019 | 12.03M |
| June 30, 2019 | 0.003M |
| March 31, 2019 | 56.18M |
| December 31, 2018 | 3.857M |
| September 30, 2018 | 1.02M |
| June 30, 2018 | 54.00M |
| March 31, 2018 | 43.92M |
| December 31, 2017 | 17.42M |
| Date | Value |
|---|---|
| September 30, 2017 | 23.63M |
| June 30, 2017 | 8.131M |
| March 31, 2017 | 15.36M |
| December 31, 2016 | 0.765M |
| September 30, 2016 | 0.48M |
| June 30, 2016 | 0.253M |
| March 31, 2016 | 278.35M |
| December 31, 2015 | 0.201M |
| September 30, 2015 | 8.522M |
| June 30, 2015 | 4.064M |
| March 31, 2015 | 195.50M |
| December 31, 2014 | 0.268M |
| September 30, 2014 | 0.581M |
| June 30, 2014 | 107.70M |
| March 31, 2014 | 1.17M |
| December 31, 2013 | 0.092M |
| September 30, 2013 | 119.37M |
| June 30, 2013 | 4.391M |
| March 31, 2013 | 7.181M |
| December 31, 2012 | 27.03M |
| September 30, 2012 | 7.384M |
| June 30, 2012 | 12.12M |
| March 31, 2012 | 7.259M |
| December 31, 2011 | 1.851M |
| September 30, 2011 | 0.923M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-354.38M
Minimum
Mar 2023
576.99M
Maximum
Mar 2021
95.69M
Average
30.17M
Median
Dec 2019
Cash from Financing (Quarterly) Benchmarks
| Pfizer Inc | 5.442B |
| Moderna Inc | -109.00M |
| Agilent Technologies Inc | -240.00M |
| Lexicon Pharmaceuticals Inc | -0.001M |
| Vaxart Inc | -0.066M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -176.78M |
| Cash from Investing (Quarterly) | -9.078M |
| Free Cash Flow | -772.77M |
| Free Cash Flow Per Share (Quarterly) | -1.500 |
| Free Cash Flow to Equity (Quarterly) | -186.25M |
| Free Cash Flow to Firm (Quarterly) | -181.70M |
| Free Cash Flow Yield | -169.6% |